Effect of perioperative chemotherapy on resection of isolated pulmonary metastases from colorectal cancer: A single center experience

• Published in: World journal of gastrointestinal oncology 2024-08, Vol.16 (8), p.3457-3470
• Main Authors: Gao, Zhao, Jin, Xuan, Wu, Ying-Chao, Zhang, Shi-Jie, Wu, Shi-Kai, Wang, Xin
• Format: Article
• Language: English
• Subjects: Retrospective Cohort Study
• ISSN: 1948-5204; 1948-5204
• DOI: 10.4251/wjgo.v16.i8.3457

Numerous studies have assessed surgical resection as a standard treatment option for patients with colorectal cancer (CRC) and resectable pulmonary metastases (PM). However, the role of perioperative chemotherapy after complete resection of isolated PM from patients with CRC patients remains controversial. We hypothesize that perioperative chemotherapy does not provide significant survival benefits for patients undergoing resection of PM from CRC. To determine whether perioperative chemotherapy affects survival after radical resection of isolated PM from CRC. We retrospectively collected demographic, clinical, and pathologic data on patients who underwent radical surgery for isolated PM from CRC. Cancer-specific survival (CSS) and disease-free survival were calculated using Kaplan-Meier analysis. Inter-group differences were compared using the log-rank test. For multivariate analysis, Cox regression was utilized when indicated. This study included 120 patients with a median age of 61.6 years. The 5-year CSS rate was 78.2%, with 36.7% experiencing recurrence. Surgical resection for isolated PM resulted in a 5-year CSS rate of 50.0% for second metastases. Perioperative chemotherapy ( = 0.079) did not enhance survival post-resection. Factors associated with improved survival included fewer metastatic lesions [hazard ratio (HR): 2.51, = 0.045], longer disease-free intervals (HR: 0.35, = 0.016), and wedge lung resections (HR: 0.42, = 0.035). Multiple PM predicted higher recurrence risk (HR: 2.22, = 0.022). The log-rank test showed no significant difference in CSS between single and repeated metastasectomy ( = 0.92). Perioperative chemotherapy shows no survival benefit post-PM resection in CRC. Disease-free intervals and fewer metastatic lesions predict better survival. Repeated metastasectomy is warranted for eligible patients.